本文選題：重組質(zhì)粒 + IL-24��； 參考：《延邊大學(xué)》2012年碩士論文

【摘要】：目的：研究重組質(zhì)粒pEGFP-N1-IL-24基因在小鼠黑色素瘤移植瘤體內(nèi)的表達(dá)及其對(duì)黑色素瘤的抑制作用。 方法： 1.B16細(xì)胞培養(yǎng)從液氮罐里取出并復(fù)蘇B16細(xì)胞,接種于含10%小牛血清的RPMI-1640培養(yǎng)液的培養(yǎng)瓶中進(jìn)行培養(yǎng),傳代。 2.黑色素瘤B16細(xì)胞小鼠皮下移植瘤模型的建立待觀察C57BL/6小鼠一周后,一般狀況良好的情況下,收集對(duì)數(shù)生長(zhǎng)期的B16細(xì)胞,在無(wú)菌條件下每只以5×10.cells/ml接種于小鼠背部皮下,觀察小鼠移植瘤的生長(zhǎng)情況。 3.IL-24基因治療黑色素瘤B16細(xì)胞小鼠移植瘤的影響將荷瘤鼠隨機(jī)分為3組,每組6只,在瘤體內(nèi)注射脂質(zhì)體包裹的重組質(zhì)粒pEGFP-N1-IL-24(10μg)為實(shí)驗(yàn)組,注射脂質(zhì)體包裹的空載質(zhì)粒pEGFP-N1(10μg)、注射PBS(0.2m1)為陰性對(duì)照組。每3天注射一次,共注射4次。每次注射藥物前先用游標(biāo)卡尺測(cè)量腫瘤的長(zhǎng)徑(L)和短徑(W),計(jì)算腫瘤體積,并繪制腫瘤的生長(zhǎng)曲線。 4.在末次注射藥物后7天斷頸處死小鼠,剝離腫瘤組織。小部分組織冰凍用于RT-PCR鑒定,剩余部分組織冰凍用于Western蛋白印跡法檢測(cè)Bax蛋白的表達(dá)。 5. RT-PCR方法檢測(cè)移植瘤組織中IL-24mRNA的表達(dá)從各組移植瘤組織中提取總RNA,逆轉(zhuǎn)錄合成cDNA,與IL-24上下游引物,進(jìn)行PCR反應(yīng),擴(kuò)增產(chǎn)物進(jìn)行瓊脂糖凝膠電泳,并查看目的條帶 6. Western蛋白印跡法檢測(cè)移植瘤組織中的Bax蛋白的表達(dá)提取各組移植瘤組織中的蛋白,進(jìn)行聚丙烯酰胺凝膠電泳,轉(zhuǎn)膜,封閉,加入抗體與目的蛋白產(chǎn)生反應(yīng),顯影、定影后,觀察目的蛋白的表達(dá)水平。 結(jié)果： 1.成功建立了黑色素瘤移植瘤小鼠模型,接種細(xì)胞后第12天小鼠皮下腫瘤直徑均達(dá)5mm,腫瘤移植率達(dá)100%； 2.腫瘤生長(zhǎng)曲線圖表明重組質(zhì)粒pEGFP-N1-IL-24組移植瘤的體積明顯小于空載質(zhì)粒pEGFP-N1組和PBS組,其差異有統(tǒng)計(jì)學(xué)意義(P0.05),而空載質(zhì)粒組和PBS組移植瘤體積則無(wú)明顯差異(P0.05)。與空載質(zhì)粒pEGFP-N1組和PBS組相比,重組質(zhì)粒pEGFP-Nl-IL-24組移植瘤生長(zhǎng)緩慢,而空載質(zhì)粒pEGFP-N1組和PBS組移植瘤生長(zhǎng)曲線幾乎平行； 3.各組的腫瘤組織中提取了RNA,進(jìn)行RT-PCR檢測(cè),擴(kuò)增產(chǎn)物經(jīng)瓊脂糖凝膠電泳顯示重組質(zhì)粒pEGFP-N1-IL-24組在611bp處有一陽(yáng)性條帶而空載質(zhì)粒pEGFP-N1組和PBS組未出現(xiàn)此預(yù)期的條帶； 4.各組移植瘤組織中提取蛋白進(jìn)行Western蛋白印記法,結(jié)果在重組質(zhì)粒pEGFP-N1-IL-24組上出現(xiàn)了Bax蛋白的表達(dá),而空載質(zhì)粒pEGFP-N1組和PBS組未出現(xiàn)Bax蛋白的表達(dá)。 結(jié)論： 1. IL-24基因在黑色素瘤組織中穩(wěn)定表達(dá)了其蛋白。 2. IL-24具有抑制黑色素瘤B16細(xì)胞小鼠移植瘤生長(zhǎng)的作用。 3. IL-24對(duì)黑色素瘤組織有促進(jìn)Bax蛋白分泌的作用。
[Abstract]:Aim: to investigate the expression of recombinant plasmid pEGFP-N1-IL-24 gene in murine melanoma xenografts and its inhibitory effect on melanoma. Methods: 1.B16 cells were extracted from liquid nitrogen tank and resuscitated. The B16 cells were cultured in RPMI-1640 culture flask containing 10% calf serum. 2. Establishment of subcutaneous tumor transplantation model of melanoma B16 cells in mice to be observed after one week after C57BL/6 mice were in good condition, B16 cells in logarithmic growth phase were collected and inoculated subcutaneously with 5 脳 10.cells/ml on the back of mice under aseptic condition. The growth of transplanted tumor in mice was observed. The effect of 3.IL-24 gene therapy on transplanted melanoma B16 cells mice were randomly divided into 3 groups, 6 mice in each group, and the recombinant plasmid pEGFP-N1-IL-24(10 渭 g encapsulated with liposome was injected into the tumor as experimental group. The blank plasmid pEGFP-N1(10 渭 g was injected with liposome, and the control group was injected with PBSX 0.2 m ~ (1). Once every 3 days, a total of 4 times. The tumor volume was calculated and the tumor growth curve was drawn by using Vernier caliper to measure the long diameter L) and the short diameter of the tumor before each injection. 4. The mice were killed 7 days after the last injection and the tumor tissue was removed. A small number of tissues were frozen for RT-PCR identification, while the rest were used for Western Western blot assay to detect the expression of Bax protein. 5. RT-PCR method was used to detect the expression of IL-24mRNA in transplanted tumor tissues. Total RNAs were extracted from each group of transplanted tumor tissues, then synthesized by reverse transcription, then reacted with IL-24 primers, reacted with PCR, amplified products were analyzed by agarose gel electrophoresis, and the target bands were examined. 6. Western Western blotting was used to detect the expression of Bax protein in the transplanted tumor tissue. The protein was extracted from the transplanted tumor tissue by polyacrylamide gel electrophoresis, transmembrane, blocking, reaction with the antibody and the target protein. The expression level of target protein was observed. Results: 1. The mouse model of melanoma transplanted tumor was established successfully. The diameter of subcutaneous tumor was 5 mm and the tumor transplant rate reached 100 mm on the 12th day after inoculation. 2. The tumor growth curve showed that the volume of transplanted tumor in the recombinant plasmid pEGFP-N1-IL-24 group was significantly smaller than that in the blank plasmid pEGFP-N1 group and the PBS group, and the difference was statistically significant (P 0.05), but there was no significant difference in the volume of the transplanted tumor between the no-load plasmid group and the PBS group. Compared with the no-load plasmid pEGFP-N1 group and PBS group, the growth of transplanted tumor was slower in the recombinant plasmid pEGFP-Nl-IL-24 group, but the growth curve was almost parallel between the no-load plasmid pEGFP-N1 group and the PBS group. 3. RNAs were extracted from tumor tissues of each group and detected by RT-PCR. Agarose gel electrophoresis showed that there was a positive band at 611bp in the recombinant plasmid pEGFP-N1-IL-24 group, but there was no such expected band in the pEGFP-N1 group and PBS group. 4. The expression of Bax protein was found in the recombinant plasmid pEGFP-N1-IL-24 group, but no Bax protein expression was found in the blank plasmid pEGFP-N1 group and PBS group. Conclusion: 1. IL-24 gene expressed its protein stably in melanoma tissue. 2. IL-24 can inhibit the growth of transplanted melanoma B 16 cells in mice. 3. IL-24 can promote the secretion of Bax protein in melanoma tissues.
【學(xué)位授予單位】：延邊大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類號(hào)】：R739.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 于楠;王金柱;張玉玖;毛玉泉;張景權(quán);譚郁彬;;原發(fā)性食管黑色素瘤的臨床和病理探討——附1例報(bào)告及文獻(xiàn)復(fù)習(xí)[J];天津醫(yī)藥;1986年11期

2 李忠,王榮朝;小腸、口腔及肺多灶性無(wú)色素性黑色素瘤1例[J];江蘇大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);1994年02期

3 汪九湘，，劉文格;黑色素瘤與多發(fā)性骨髓瘤并存一例[J];河南腫瘤學(xué)雜志;1996年06期

4 楊維春,李世芳;脈絡(luò)膜黑色素瘤術(shù)后9年單發(fā)肝臟轉(zhuǎn)移病例報(bào)告[J];華北煤炭醫(yī)學(xué)院學(xué)報(bào);1999年03期

5 王卓才,賴日權(quán),羅祝泉;肝惡性黑色素瘤1例[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2001年06期

6 傅濤,魏文斌,王陽(yáng),劉小超;血清黑色素瘤活性抑制蛋白與葡萄膜黑色素瘤[J];中華眼底病雜志;2005年03期

7 楊秀珍;張曉梅;徐山淡;;顱內(nèi)原發(fā)性黑色素瘤誤診一例[J];中華放射學(xué)雜志;2006年07期

8 楊景春,劉子勇,孫揚(yáng),蘇肖漢,馬遠(yuǎn)平;CO_2激光照射實(shí)驗(yàn)性黑色素瘤觀察[J];中國(guó)醫(yī)科大學(xué)學(xué)報(bào);1986年Z1期

9 呂德志;錢俊甫;張友昌;;黑色素瘤誤診雞眼一例[J];中國(guó)實(shí)用外科雜志;1988年08期

10 郭華北，余裕民，姜程茂，蔣秉坤;血清S100IRMA對(duì)黑色素瘤的臨床應(yīng)用價(jià)值[J];標(biāo)記免疫分析與臨床;1995年04期

相關(guān)會(huì)議論文 前10條

1 吳緬;;MicroRNA調(diào)控黑色素瘤發(fā)生機(jī)制(英文)[A];第三屆細(xì)胞結(jié)構(gòu)與功能的信號(hào)基礎(chǔ)研討會(huì)論文摘要[C];2010年

2 黎川;;黑色素瘤的MRI診斷[A];2010中華醫(yī)學(xué)會(huì)影像技術(shù)分會(huì)第十八次全國(guó)學(xué)術(shù)大會(huì)論文集[C];2010年

3 許宇;趙培泉;朱穎;;視盤上的黑色素細(xì)胞瘤抑或是黑色素瘤[A];中國(guó)眼底病論壇·全國(guó)眼底病專題學(xué)術(shù)研討會(huì)論文匯編[C];2008年

4 王國(guó)華;;惡性黑色素瘤胃轉(zhuǎn)移的X線表現(xiàn)(附5例分析)[A];全國(guó)非血管性與血管性介入新技術(shù)學(xué)術(shù)研討大會(huì)（第二屆介入放射學(xué)新技術(shù)提高班、第二屆河南省腫瘤介入診療學(xué)術(shù)大會(huì)）論文匯編[C];2004年

5 賈蘭青;羅利群;張友會(huì);;轉(zhuǎn)導(dǎo)B_7-1基因消除IFN-γ對(duì)黑色素瘤轉(zhuǎn)移潛力的增強(qiáng)作用[A];面向21世紀(jì)的科技進(jìn)步與社會(huì)經(jīng)濟(jì)發(fā)展（下冊(cè)）[C];1999年

6 胡巍;張超;方蕓;;霧化吸入羥基喜樹堿對(duì)小鼠黑色素瘤肺轉(zhuǎn)移的藥效學(xué)及體外作用機(jī)制研究[A];2010年江蘇省藥學(xué)大會(huì)暨第十屆江蘇省藥師周大會(huì)論文集[C];2010年

7 王寅;林文;殷明;姜恅英;陳新生;;5—脂氧合酶對(duì)黑色素瘤A375粘附及整合素表達(dá)的作用[A];海峽兩岸三地藥理學(xué)學(xué)術(shù)報(bào)告會(huì)論文匯編[C];2001年

8 徐輝;唐桂波;;黑色素瘤腦轉(zhuǎn)移的MRI表現(xiàn)[A];中華醫(yī)學(xué)會(huì)第十三屆全國(guó)放射學(xué)大會(huì)論文匯編（上冊(cè)）[C];2006年

9 胡巍;張超;方蕓;;霧化吸入羥基喜樹堿對(duì)小鼠黑色素瘤肺轉(zhuǎn)移的藥效學(xué)及體外作用機(jī)制研究[A];2010施慧達(dá)杯第十屆全國(guó)青年藥學(xué)工作者最新科研成果交流會(huì)論文集[C];2010年

10 安菊生;吳令英;李寧;俞高志;劉麗影;;原發(fā)女性生殖道黑色素瘤42例臨床分析[A];中華醫(yī)學(xué)會(huì)第九次全國(guó)婦科腫瘤學(xué)術(shù)會(huì)議論文匯編[C];2006年

相關(guān)重要報(bào)紙文章 前10條

1 王倫 劉晨;探索黑色素瘤治療新技術(shù)[N];保健時(shí)報(bào);2009年

2 健康時(shí)報(bào)特約記者 管九蘋;澳大利亞免費(fèi)普查黑色素瘤[N];健康時(shí)報(bào);2010年

3 實(shí)習(xí)生 易立;黑色素瘤,是否無(wú)藥可治？[N];科技日?qǐng)?bào);2011年

4 本報(bào)記者 聶國(guó)春;專家：黑色素瘤可防可治[N];中國(guó)消費(fèi)者報(bào);2011年

5 記者 張e

本文編號(hào)：1952512